GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Heritage Pharmaceuticals and Apotex will pay $49.1 million in a settlement with Pennsylvania, New Jersey and other states.

It follows concern in several countries over the presence of impurities in Zantac and other ranitidine products. Canada and France have already announced Zantac recalls. The US and the European ...

Patients received either Protonix 10 mg, 20 mg, or 40 mg delayed-release tablets once daily or ranitidine 150 mg twice daily. Protonix 20 mg and 40 mg was significantly superior to ranitidine at ...

Prolonged Q-T interval Hospitalization 80 (07/09/2001, occurred 9/27/1991) 37, M Droperidol 125 mg, ranitidine, clomeiethiazole, nifedipine, metoprolol, potassium chloride Ventricular fibrillation ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $2.2bn ...

quinolones (ofloxacin and gatifloxacin), ranitidine, sertraline, thioridazine, trazodone, venlafaxine, verapamil, and a nonprescription nasal inhaler. False-positive results for amphetamine and ...